Bio-Neuroscience is a world-leading global summit focused on innovations in the CNS field that brings together investors, researchers and leading decision-makers in the biotech and pharmaceutical industries. The conference is organized by Broadreach Global and is known for its selective selection of companies that are given the opportunity to present their projects and strategies to an international audience of potential partners and investors.

AlzeCure has been selected in competition with other companies to present its operations and project portfolio within diseases of the central nervous system.

”It is an important recognition of AlzeCure's project portfolio and our strategic focus on neurodegenerative diseases and pain to be selected to present at one of the leading conferences in the field. The conference provides an attractive platform for dialogue with both industrial players and financial investors, and we look forward to participating and presenting the company,” said Martin Jönsson, CEO of AlzeCure Pharma.

The twelve participating companies have been selected from an international and highly competitive pool following a rigorous evaluation of scientific innovation, clinical progress, therapeutic strategy and commercial potential. The companies come from Europe, the UK, North America and Australia, and represent a broad and diversified portfolio of breakthrough approaches in both neurology and psychiatry, with development programs spanning from preclinical to late clinical phases.

Bio-Neuroscience 2026 brings together leading investment companies and venture capital firms focused on the CNS field, e.g. EQT Life Sciences, F-Prime Capital, AbbVie Ventures, Sofinnova Partners, and BioGeneration Ventures (BGV). In addition, leading decision-makers from global pharmaceutical companies, e.g. Eli Lilly, Sanofi, MSD, Johnson & Johnson, Lundbeck, and Boehringer Ingelheim, will attend.